# Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

> **NCT00925054** · PHASE2 · COMPLETED · sponsor: **BioMarin Pharmaceutical** · enrollment: 40 (actual)

## Conditions studied

- Phenylketonuria

## Interventions

- **DRUG:** rAvPAL-PEG 0.001 mg/kg
- **DRUG:** rAvPAL-PEG 0.003 mg/kg
- **DRUG:** rAvPAL-PEG 0.01 mg/kg
- **DRUG:** rAvPAL-PEG 0.03 mg/kg
- **DRUG:** rAvPAL-PEG 0.1 mg/kg

## Key facts

- **NCT ID:** NCT00925054
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00925054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00925054, "Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT00925054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*